• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Aclaris Therapeutics Inc. (Amendment)

    2/14/24 5:01:20 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRS alert in real time by email
    SC 13G/A 1 tm245429d10_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    ACLARIS THERAPEUTICS, INC.

    (Name of Issuer)

     

    Common Stock, $0.00001 par value per share

    (Title of Class of Securities)

     

    00461U105

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨  Rule 13d-1(b)
    x  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 00461U105

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF 5

    SOLE VOTING POWER

     

    0

     

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH
    6

    SHARED VOTING POWER

     

    0

     

    REPORTING

    PERSON

    WITH:
    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

     

           

     

     

     

     

    CUSIP No. 00461U105

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

     

     

    NUMBER OF

    5

    SOLE VOTING POWER

     

    0

     

    SHARES

    BENEFICIALLY

    OWNED BY

    6

    SHARED VOTING POWER

     

    0

    EACH

    REPORTING

    PERSON

    WITH:
    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

     

           

     

     

     

     

    CUSIP No. 00461U105

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

     

     

    NUMBER OF

    5

    SOLE VOTING POWER

     

    0

     

    SHARES

    BENEFICIALLY

    OWNED BY

    6

    SHARED VOTING POWER

     

    0

    EACH

    REPORTING

    PERSON

    WITH:
    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

     

           

     

     

     

     

    CUSIP No. 00461U105

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     

    NUMBER OF

    5

    SOLE VOTING POWER

     

    0

     

    SHARES

    BENEFICIALLY

    OWNED BY

    6

    SHARED VOTING POWER

     

    0

    EACH

    REPORTING

    PERSON

    WITH:
    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

           

     

     

     

     

    Item 1(a). Name of Issuer:

     

    Aclaris Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    701 Lee Road, Suite 103, Wayne, Pennsylvania 19087

     

    Item 2(a).Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    RA Capital Management, L.P. (“RA Capital”)

    Peter Kolchinsky

    Rajeev Shah

    RA Capital Healthcare Fund, L.P. (the “Fund”)

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is:

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

    RA Capital is a Delaware limited partnership. Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, $0.00001 par value per share (“Common Stock”)

     

    Item 2(e).CUSIP Number:

     

    00461U105

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following      x.

     

     

     

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    Exhibit List

     

    Exhibit 1: Joint filing agreement

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024

     

    RA CAPITAL MANAGEMENT, L.P.  
       
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Authorized Signatory  
       
    PETER KOLCHINSKY  
       
    /s/ Peter Kolchinsky  
       
    RAJEEV SHAH  
       
    /s/ Rajeev Shah  
       
    RA CAPITAL HEALTHCARE FUND, L.P.  
       
    By: RA Capital Healthcare Fund GP, LLC  
    Its: General Partner  
       
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Manager  

     

     

     

     

    EXHIBIT 1

     

    AGREEMENT

     

    This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).

     

    Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Stock $0.00001 per share of Aclaris Therapeutics, Inc. beneficially owned by them from time to time.

     

    Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

     

    This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

     

    Executed and delivered as of the date first above written.

     

    RA CAPITAL MANAGEMENT, L.P.  
       
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Authorized Signatory  
       
    PETER KOLCHINSKY  
       
    /s/ Peter Kolchinsky  
       
    RAJEEV SHAH  
       
    /s/ Rajeev Shah  
       
    RA CAPITAL HEALTHCARE FUND, L.P.  
       
    By: RA Capital Healthcare Fund GP, LLC  
    Its: General Partner  
       
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Manager  

     

     

     

    Get the next $ACRS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRS

    DatePrice TargetRatingAnalyst
    7/10/2025$6.00Overweight
    Piper Sandler
    5/28/2025$8.00Outperform
    Wedbush
    3/18/2025Overweight
    Cantor Fitzgerald
    12/23/2024$20.00Neutral → Buy
    H.C. Wainwright
    11/20/2024Neutral → Overweight
    Cantor Fitzgerald
    11/19/2024$2.00 → $7.00Market Perform → Outperform
    Leerink Partners
    11/19/2024$8.00Neutral → Buy
    BTIG Research
    11/19/2024$2.00 → $7.00Hold → Buy
    Jefferies
    More analyst ratings

    $ACRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    - Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target - - Advanced Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) into Phase 2 Trial in Atopic Dermatitis (AD); Patient Dosing Underway - - Initiated Dosing in Phase 1a/1b Clinical Program for Anti-TSLP/IL-4R Bispecific Antibody ATI-052 - - Strong Cash Runway Expected to Fund Operations into the Second Half of 2028 - WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory

    8/7/25 6:59:32 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

    - Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved Therapies with Potential for Improved Tolerability, Supporting Exploration of Higher Doses in Future Clinical Trials - - Pharmacodynamic Results Validate Therapeutic Potential of ITK Inhibition and Corroborate Potential of Aclaris' ITK Franchise - - Management to Host a Conference Call to Discuss Results Today at 5:00PM EDT - WAYNE, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel pro

    7/29/25 4:01:47 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Announces Leadership Transition

    - Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D. will Continue to Support Aclaris as Special Scientific Advisor to the Chief Executive Officer through March 2026 as Part of Planned Retirement - WAYNE, Pa., July 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Roland Kolbeck, Ph.D. has been appointed as Chief Scientific Officer, replacing Joe Monahan, Ph.D. who will remain with the Company as Special Scientific Advisor to the Chief Executive Officer through the first quarter of 2026 as

    7/28/25 8:45:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Scientific Officer Kolbeck Roland Wilhelm

    4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

    8/5/25 4:33:44 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Kolbeck Roland Wilhelm

    3 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

    8/5/25 4:31:31 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Milano Vincent converted options into 4,793 shares, increasing direct ownership by 38% to 17,316 units (SEC Form 4)

    4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

    6/9/25 4:20:29 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ACRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ACRS
    SEC Filings

    View All

    Director Mehra Anand bought $1,499,998 worth of shares (666,666 units at $2.25), increasing direct ownership by 1,537% to 710,030 units (SEC Form 4)

    4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

    11/20/24 4:20:04 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Leonard Braden Michael bought $472,757 worth of shares (373,569 units at $1.27) (SEC Form 4)

    4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

    8/5/24 3:57:34 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Leonard Braden Michael bought $359,010 worth of shares (273,730 units at $1.31) (SEC Form 4)

    4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

    7/31/24 4:10:09 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler resumed coverage on Aclaris Therapeutics with a new price target

    Piper Sandler resumed coverage of Aclaris Therapeutics with a rating of Overweight and set a new price target of $6.00

    7/10/25 8:47:17 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Aclaris Therapeutics with a new price target

    Wedbush initiated coverage of Aclaris Therapeutics with a rating of Outperform and set a new price target of $8.00

    5/28/25 8:54:54 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Aclaris Therapeutics

    Cantor Fitzgerald resumed coverage of Aclaris Therapeutics with a rating of Overweight

    3/18/25 8:23:58 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Aclaris Therapeutics Inc.

    10-Q - Aclaris Therapeutics, Inc. (0001557746) (Filer)

    8/7/25 4:31:13 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)

    8/7/25 7:15:40 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)

    7/29/25 4:15:18 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/25/24 11:02:19 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/22/24 4:00:23 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/21/24 4:51:50 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    Financials

    Live finance-specific insights

    View All

    Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    - Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target - - Advanced Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) into Phase 2 Trial in Atopic Dermatitis (AD); Patient Dosing Underway - - Initiated Dosing in Phase 1a/1b Clinical Program for Anti-TSLP/IL-4R Bispecific Antibody ATI-052 - - Strong Cash Runway Expected to Fund Operations into the Second Half of 2028 - WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory

    8/7/25 6:59:32 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

    - Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved Therapies with Potential for Improved Tolerability, Supporting Exploration of Higher Doses in Future Clinical Trials - - Pharmacodynamic Results Validate Therapeutic Potential of ITK Inhibition and Corroborate Potential of Aclaris' ITK Franchise - - Management to Host a Conference Call to Discuss Results Today at 5:00PM EDT - WAYNE, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel pro

    7/29/25 4:01:47 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

    - Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial res

    5/8/25 6:50:51 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    Leadership Updates

    Live Leadership Updates

    View All

    Aclaris Therapeutics Announces Leadership Transition

    - Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D. will Continue to Support Aclaris as Special Scientific Advisor to the Chief Executive Officer through March 2026 as Part of Planned Retirement - WAYNE, Pa., July 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Roland Kolbeck, Ph.D. has been appointed as Chief Scientific Officer, replacing Joe Monahan, Ph.D. who will remain with the Company as Special Scientific Advisor to the Chief Executive Officer through the first quarter of 2026 as

    7/28/25 8:45:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

    WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has been appointed as Chief Medical Officer. Dr. Hall's extensive medical and clinical development experience in areas including immunology and antibody development will be essential as he leads Aclaris' clinical strategy to fully leverage the opportunities in the Company's portfolio of immuno-inflammatory product candidates. "At Aclaris, our vision is to drive the leading edge of therapeutic innovation in I&I; Jesse shares this vision and

    4/29/25 7:00:32 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

    CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company's Board of Directors.

    4/23/24 8:00:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care